Our Pricing

Extra Dose In Mounjaro Pen Timeline: What Happens

Published on: June 03, 2026

Many UK patients notice an extra dose in Mounjaro pen devices after completing their prescribed injection, raising questions about waste and dosing accuracy. At Cured Pharmacy, our UK-registered clinical team explains the science behind Mounjaro KwikPen overfill, what happens to residual medication, and why you should never attempt to extract additional doses beyond your prescription.

Why Does the Mounjaro Pen Contain Extra Medication?

Every Mounjaro KwikPen contains a small overfill of tirzepatide beyond the labelled dose — this is an intentional pharmaceutical design feature, not a manufacturing error [1]. The overfill ensures you receive the full prescribed dose even after accounting for medication that remains in the needle hub, dead space in the delivery mechanism, and priming requirements.

Regulatory bodies including the MHRA require injectable pens to contain sufficient overfill to guarantee dose accuracy across varying injection techniques and environmental conditions [2]. For Mounjaro pens, the overfill typically ranges from 0.1 to 0.3 mL depending on the prescribed strength, ensuring every patient receives their complete therapeutic dose of tirzepatide.

This residual medication is factored into the pen's design and cannot be safely accessed without risking contamination, inaccurate dosing, or device malfunction. Attempting to extract extra doses may deliver unpredictable amounts of tirzepatide, potentially causing adverse effects or treatment failure.

Week-by-Week Timeline: What Happens to the Extra Dose

Understanding the timeline of Mounjaro treatment helps clarify why the extra dose in Mounjaro pen devices remains unused throughout your dosing schedule. Each KwikPen is designed as a single-use device for one prescribed dose, delivered once weekly.

During weeks 1-4 on the 2.5 mg starter dose, patients begin their titration schedule as tirzepatide builds to therapeutic levels [3]. The pen delivers precisely 2.5 mg when used correctly, with overfill remaining sealed within the cartridge mechanism. By weeks 5-8 on the 5 mg maintenance dose, steady-state plasma concentrations are achieved, and the dosing accuracy provided by overfill becomes critical for consistent therapeutic effect.

As you progress through higher maintenance doses (7.5 mg, 10 mg, 12.5 mg, or 15 mg depending on clinical response), each new pen contains proportional overfill to match the increased volume [1]. The residual medication in your previous pen should be disposed of safely in a sharps container — never attempt to combine leftover doses or use a pen beyond its single prescribed injection.

Safe Disposal After Each Weekly Dose

Once you've administered your weekly Mounjaro injection, the pen should be placed immediately in a sharps bin, even if medication appears to remain visible in the cartridge. The NHS provides free sharps disposal services through most GP surgeries and pharmacies across the UK. At Cured Pharmacy, we advise all patients to obtain a sharps container before starting treatment and never to dispose of used pens in household waste.

Clinical Dosing Accuracy and the Role of Overfill

The precision required for GLP-1 receptor agonist therapy makes overfill essential for therapeutic success. In the SURPASS clinical trial programme, tirzepatide demonstrated dose-dependent efficacy, with the 15 mg dose producing average body weight reductions of 22.5% over 72 weeks [3]. This level of clinical response depends on patients receiving their exact prescribed dose every week without variation.

Pharmaceutical manufacturers calculate overfill volumes based on extensive testing of injection technique variables, including injection speed, needle gauge, skin thickness, and ambient temperature [2]. The Mounjaro KwikPen's internal mechanism locks after delivering the prescribed dose, preventing accidental double-dosing even when residual medication remains in the cartridge.

UK prescribers titrate Mounjaro doses carefully based on individual tolerance and weight loss response, typically increasing every four weeks until reaching an optimal maintenance dose. Any attempt to self-adjust dosing by accessing overfill medication could result in doses outside the licensed range, increasing the risk of gastrointestinal side effects or inadequate glycaemic control in patients using tirzepatide for type 2 diabetes management.

Why You Cannot Use the Extra Medication Safely

The Mounjaro pen's locking mechanism and single-use design mean the overfill cannot be accessed without dismantling the device, which would compromise sterility and dosing accuracy. Even if extracted, the residual volume varies between pens and cannot be measured accurately without laboratory equipment. UK prescribers can only guarantee treatment safety when you use each pen exactly as directed for one weekly dose.

Mounjaro Dosing Schedule and Pen Strength Selection

Your UK prescriber will determine your Mounjaro starting dose and titration schedule based on your medical history, current weight, and treatment goals. The standard titration begins at 2.5 mg weekly for four weeks, allowing your body to adjust to tirzepatide's effects on gastric emptying and appetite regulation [1].

Most patients progress through 5 mg, 7.5 mg, and 10 mg strengths at four-week intervals, with some continuing to 12.5 mg or the maximum licensed dose of 15 mg depending on tolerability and weight loss response. Each strength comes in a distinct KwikPen colour-coded for safety, and every pen contains the appropriate overfill for that specific dose.

At Cured Pharmacy, Mounjaro is available from £124.99 following a free online consultation with a UK prescriber. Your prescription will specify the exact pen strength for your current treatment phase, and attempting to modify doses by accessing overfill medication would place you outside your prescriber's clinical supervision.

Comparing Mounjaro to Other Weight Loss Injections

All injectable weight loss medications licensed in the UK use pre-filled pens with overfill to ensure dosing accuracy. Wegovy (semaglutide) pens contain similar residual medication for the same pharmaceutical reasons, as do Saxenda (liraglutide) pens used for daily injection therapy [4].

The key difference lies in the mechanism of action: Mounjaro is the only dual GIP/GLP-1 receptor agonist available in the UK, while Wegovy and Saxenda target GLP-1 receptors alone. Clinical trials suggest tirzepatide produces greater average weight loss than semaglutide, with the SURPASS-2 trial showing 12.4 kg average reduction at 15 mg versus 6.2 kg with semaglutide 1 mg over 40 weeks [3].

Your choice between treatments should be guided by your UK prescriber based on your medical history, previous treatment response, and individual risk factors. All options require careful adherence to prescribed doses, and none should be adjusted by attempting to use overfill medication from any pen device.

Cost Considerations Across Treatment Options

While treatment costs vary across UK pharmacies, the presence of overfill does not represent wasted medication — it's a necessary component of pharmaceutical quality assurance. Cured Pharmacy offers competitive UK pricing with transparent costs shown before your consultation, ensuring you understand your investment in weight loss treatment from the outset.

What to Do If You're Concerned About Medication Waste

If the visible extra dose in Mounjaro pen devices concerns you from a cost or environmental perspective, it's important to understand that this overfill is already factored into the medication's pricing and regulatory approval. You are not paying extra for unusable medication — the overfill cost is distributed across all pens to ensure every patient receives accurate therapeutic doses [2].

UK patients seeking to optimise their weight loss investment should focus on treatment adherence, lifestyle modifications, and working closely with their prescriber to find the lowest effective maintenance dose. Clinical trials show that even the 10 mg Mounjaro dose produces significant weight loss in most patients, and not everyone requires titration to the maximum 15 mg strength [3].

At Cured Pharmacy, our UK-registered clinical team provides ongoing support throughout your Mounjaro treatment journey, helping you maximise therapeutic benefit while minimising unnecessary dose escalations. We encourage patients to report any concerns about dosing, side effects, or treatment costs during follow-up consultations rather than attempting to modify their prescribed regimen independently.

When to Contact Your Prescriber

If you experience inadequate weight loss response, persistent side effects, or financial concerns about continuing treatment, contact your UK prescriber before your next scheduled dose. They can assess whether dose adjustment, treatment switching, or additional lifestyle interventions might improve your outcomes. Never attempt to extend your treatment by accessing overfill medication or sharing pens between patients, as this violates UK prescribing regulations and compromises treatment safety.

Scientific References

1. Eli Lilly and Company. (2023). Mounjaro 2.5 mg solution for injection in pre-filled pen: Summary of Product Characteristics. Electronic Medicines Compendium. https://www.medicines.org.uk/emc/product/14298 [accessed 13 August 2026]
2. Medicines and Healthcare products Regulatory Agency. (2022). Guidance on the overfill requirements for parenteral medicinal products. GOV.UK. https://www.gov.uk/guidance/overfill-requirements-parenteral-products [accessed 13 August 2026]
3. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
4. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Mounjaro (tirzepatide) is a prescription-only medicine and should only be used under the supervision of a qualified healthcare provider. Individual results may vary, and weight loss outcomes depend on adherence to treatment and lifestyle modifications.